Trading Update

Hikma Pharmaceuticals Plc
17 January 2008


                   Update on trading and reporting timetable


LONDON, 17 January 2008 - Hikma Pharmaceuticals PLC ('Hikma') (LSE: HIK) (DIFX:
HIK), the multinational pharmaceuticals group, confirms that since the
publication of its pre-close trading statement on 14 December 2007 there has
been no change to its expectations for the 2007 financial year or its outlook
for 2008.  Hikma also announces that it will make the preliminary announcement
of its results for the year ended 31 December 2007 on 18 March 2008, updating
the previously advised date of 12 March 2008.  Consequently, the corresponding
close period will begin on 18 January 2008.


                                    - ENDS -

Enquiries:


Hikma Pharmaceuticals PLC
Susan Ringdal                                    [phone]
Investor Relations Director

Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed         [phone]


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products.  Hikma operates through three
businesses: 'Branded', 'Injectables' and 'Generics', based principally in the
Middle East and North Africa ('MENA'), where it is a market leader and sells
across 18 countries, the United States and Europe.  In 2006, Hikma achieved
revenues of $317 million (2005 $262 million) and profit attributable to
shareholders was $55 million (2005 $44 million).  At 31 December 2006, the Group
had over 2,400 employees.  For news and other information, please visit
www.hikma.com.






                      This information is provided by RNS
            The company news service from the London Stock Exchange